drug

MK-3795

Phase 2updated 3mo ago

by $MRK Merck & Co., Inc.

Phase 2

community read0 votes

all catalysts(0)

nothing on the calendar yet

Trials studying MK-3795

phase2MK-3795 (PT2385) for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma (MK-3795-003)completedn=4
phase1A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001)active not recruitingn=110

News(0)

no news has mentioned this drug yet

Data sources

ClinicalTrials.gov

last refreshed just now

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug

save

MK-3795

Phase 2updated 3mo ago

by $MRK Merck & Co., Inc.

Phase 2

community read0 votes

all catalysts(0)

nothing on the calendar yet

Trials studying MK-3795

phase2MK-3795 (PT2385) for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma (MK-3795-003)completedn=4
phase1A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001)active not recruitingn=110

News(0)

no news has mentioned this drug yet

Data sources

ClinicalTrials.gov

last refreshed just now

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

MK-3795

all catalysts(0)

Trials studying MK-3795

News(0)

Report a data issue

comments(0)

MK-3795

all catalysts(0)

Trials studying MK-3795

News(0)

Report a data issue

comments(0)